The instruction for medical use
of Dona® medicine
the Trade name
the International unlicensed
name Glycosamine Dosage Form Powder for preparation of solution for intake of 1500 mg
One bag contains
active agent: crystal sulfate of a glycosamine – 1884 mg
(it is equivalent a glycosamine to sulfate of 1500 mg and sodium chloride of 384 mg),
excipients: aspartame, citric acid, makrogol 4000, sorbitol
Crystal powder of white color.
Anti-inflammatory, nonsteroid drugs others.
The code of automatic telephone exchange M01AX05
Pharmacokinetics Absorption properties in digestive tract of 90%, bioavailability of 26%, elimination half-life of 70 hours. After intake, drug is quickly distributed in extravasated liquids, including synovial fluid. Linking of a glycosamine with proteins is unknown. The fraction of a glycosamine which is not metabolized or does not contact proteins of plasma, is excreted mainly with urine and a stake.
The Glycosamine pharmacodynamics sulfate, active component of the drug Dona®, represents salt of a natural amino-monosakharidny glycosamine which physiologically contains in an organism. The glycosamine made from glucose is used for biosynthesis of proteoglycans of an articulate cartilage. The exogenous glycosamine plays the main role in biosynthesis of glikozaminoglikan of a cartilage and stimulates chondrocytes for production of proteoglycans. A glycosamine sulfate inhibits action of some main mediators of inflammatory process and activity of the enzymes destroying a cartilaginous basis such as collagenase and phospholipase of A2 and also other substances leading to damage of fabrics: superoxidic radicals, lizosomalny enzymes.
– treatment of symptoms of an osteoarthritis, in particular pain and functional limitation
the Route of administration and doses
Inside. Contents of one bag are dissolved in 200 ml of water, accepted in 1 times a day. The symptomatic effect occurs in 2-3 weeks after drug use. Duration and the scheme treatment are appointed by the attending physician. Safety and efficiency of a glycosamine of sulfate for a course of treatment, duration up to three years, was confirmed in clinical trials.
– a headache, drowsiness, increased fatigue
– diarrhea, a constipation, an abdominal distension and an abdominal pain
– an erythema, an itching, skin rash
Side effects with an unknown frequency: allergic reactions, dizzinesses, a disorder of vision,
the Contraindication hair loss
– individual hypersensitivity to a glycosamine to sulfate and other components of drug
– phenylketonuria as drug contains aspartame which is a phenylalanine source
– hereditary intolerance of fructose as with structure of a product there is a sorbitol
– an allergy to seafood
– children’s age up to 18 years
– pregnancy and the period of a lactation
It is compatible to non-steroidal anti-inflammatory drugs, paracetamol and glucocorticosteroids.
At simultaneous use, the glycosamine can strengthen effect of oral anticoagulants.
The glycosamine strengthens absorption of tetracyclines.
With care to use drug at – bronchial asthma and diabetes.
When using drug at patients from the glucose broken by tolerance expressed by a liver and renal failure the medical control is necessary.
To the patients who are on low – a sodium diet, it is necessary to take into account that each package of a sachet contains 151 mg of sodium.
The feature of influence of medicine on ability to run the vehicle or potentially dangerous mechanisms
of Influences which can affect ability of driving and work with potentially dangerous mechanisms is not shown.
Cases of accidental or deliberate overdose are not recorded. However, in case of overdose, it is necessary to see a doctor.
A form of release and packing
On 3950 mg (1500 mg of a glycosamine of sulfate) in bags from the three-layer material made of the paper, aluminum and polyethylene soldered together in the thermal way from four parties. The polyethylene film directly adjoins to bag contents.
On 20 or 30 bags together with the instruction for medical use in the state and Russian languages place in a pack from cardboard.
To Store storage conditions at a temperature not over 250C.
To store out of children’s reach!
not to apply a period of storage after the expiry date specified on packing!
According to the prescription
Rottapharm Ltd. Producer, Ireland
Damastown Industrial the Park, Mulkhaddart, Dublin 15
The name and the country of the owner of the registration certificate
Rottapharm, S.p.A, Italy
the Address of the organization accepting in the territory of the Republic of Kazakhstan claims from consumers on quality of products:
Moscow representative office of firm S.P.A. Rottapharm.
(Italy) 117198, Moscow, Leninsky Avenue 113/1, office 404B
Ph.: (495) 933-67-94, fax: (495) 937-85-01